Status:
UNKNOWN
Definitive Therapy for Oligometastatic Solid Malignancies
Lead Sponsor:
Rocky Mountain Cancer Centers
Conditions:
Stage IV or Recurrent Carcinoma or Sarcoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact...
Detailed Description
Up to recently it has been assumed that in the setting of metastatic solid tumors, locoregional control of clinically apparent metastases does not substantially impact survival due to undetectable mic...
Eligibility Criteria
Inclusion
- 4 or less distinct sites of active disease. Locoregional disease counts as one site
- All sites of disease can safely be encompassed by radiation fields to doses ≥ 45 Gy (biologic equivalent dose) and/or removed completely with surgery and/or completely ablated with other appropriate site-specific techniques.
- sufficient blood cell counts and adequate liver function
Exclusion
- Hematologic malignancies
- Distinct sites of disease \> 4
- Karnofsky Performance Status \< 70
- Unexplained weight loss \> 10 %
- HIV, chronic viral hepatitis, or any chronically active infection
- Life expectancy \< 6 months for any reason
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT01898962
Start Date
December 1 2005
End Date
December 1 2018
Last Update
July 15 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado, United States, 80012
2
Rocky Mountain Cancer Centers - Boulder
Boulder, Colorado, United States, 80303
3
Rocky Mountain Cancer Centers - Littleton
Littleton, Colorado, United States, 80120
4
Rocky Mountain Cancer Centers - Thornton
Thornton, Colorado, United States, 80260